NextBioMedical Co

NextBioMedical Co Financing Cash Flow

The Net Financing Cash Flow of NextBioMedical Co (389650.KQ) as of Nov 20, 2026 is 28.35 B KRW. In the previous year, Net Financing Cash Flow was 973.63 M KRW — a change of 2,811.69% (higher).

Financing Cash Flow

28.35 BKRW

YoY

2,811.69%

Last updated:

Net Financing Cash Flow of NextBioMedical Co is 2024 28.35 B KRW. Net Financing Cash Flow of NextBioMedical Co was 2023 973.63 M KRW. It decreases by 2,811.69% higher compared to the previous year.

The NextBioMedical Co Financing Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financing Cash Flow
Date
Financing Cash Flow
Jan 1, 2022
95.17 M KRW
Jan 1, 2023
973.63 M KRW
Jan 1, 2024
28.35 B KRW
The NextBioMedical Co Financing Cash Flow history
YEARFinancing Cash FlowYoY
28.35 BKRW+2,811.69%
973.63 MKRW+923.08%
95.17 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

NextBioMedical Co Stock analysis

What does NextBioMedical Co do? NextBioMedical Co Ltd generates revenue through the manufacturing and sales of medical equipment, including endoscopic hemostatic agents and vascular embolic microspheres. The company focuses on research and development within the health care equipment and supplies sector, targeting healthcare providers and medical institutions that require specialized equipment for procedures such as endoscopy and vascular interventions. Its products are designed to address specific clinical needs, supporting both diagnostic and therapeutic applications in medical settings. The company operates in the Health Care Equipment & Supplies industry, with a primary focus on Korea-based manufacturing and sales. Its product portfolio includes endoscopic hemostatic agents, which are used to control bleeding during endoscopic procedures, and vascular embolic microspheres, utilized in embolization treatments for vascular conditions. These products are sold to hospitals and medical facilities that require advanced medical solutions for patient care. NextBioMedical Co Ltd's business model relies on the consistent demand for specialized medical equipment in the healthcare sector. By developing and commercializing products such as endoscopic hemostatic agents and vascular embolic microspheres, the company serves healthcare providers seeking reliable and innovative tools for minimally invasive procedures. The company's research and development efforts aim to enhance product efficacy and expand its market presence within the medical equipment industry. NextBioMedical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about NextBioMedical Co stock

Net Financing Cash Flow of NextBioMedical Co is 28.35 B KRW in 2024.

Net Financing Cash Flow of NextBioMedical Co changed from 973.63 M KRW to 28.35 B KRW, representing a 2,811.69% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Financing Cash Flow NextBioMedical Co since 2006 – with annual values, charts, and detailed analysis.

Financing cash flow measures cash flows from debt issuance/repayment, equity transactions, and dividend payments.

Net Financing Cash Flow's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Financing Cash Flow's NextBioMedical Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — NextBioMedical Co

All Key Metrics — NextBioMedical Co